NewswireTODAY - /newswire/ - Monrovia, CA, United States, 2010/11/23 - Jeremy Barton, VP of Oncology at Biogen Idec will be the keynote presenter on “Targeted Drug Delivery: How Far from the Bulls Eye?” at GTCbio’s Cancer Drugs Research & Development Conference on January 27-28, 2011 in San Diego, CA.

Dr. Barton will address why the narrow therapeutic window of most cytotoxic drugs has limited their benefit in the clinic and normal tissue toxicity constrains the dose that can safely be administered. Linkage of a toxin to an antibody whose target may be an internalizing tumor specific antigen has the potential to achieve tumor selectivity relative to normal tissue and thereby improve the efficacy of the drug. The last 20 years have seen dramatic advances in the technologies which are used to construct such antibody drug conjugates (ADC) and there has been recent validation in the clinic of two different linkers (which bind the toxin to the antibody) and for two different toxins. This presentation will summarize the desired properties of an ADC and will show how the technological advances have contributed to the current success of such molecules. Clinical data from the two lead candidates will be presented and future advances and challenges will be discussed.

Benefits:

• An understanding of the ideal properties of an ADC;
• An introduction to ADC technology;
• A summary of the current clinical status of ADCs;
• Some thoughts for the future of these molecules in the treatment of cancer.

Dr. Barton, has 18 years experience in all phases of oncology drug development and commercialization activities in the pharmaceutical industry and has worked in Switzerland, the UK and the United States. Prior to joining Biogen Idec in July 2006, he held senior clinical research roles at Millennium, Elan, Glaxo Wellcome and Seattle Genetics as well as having his own consulting company. He currently manages the Oncology Medical Research Group at Biogen Idec. Dr. Barton is Board Certified in Internal Medicine and Clinical Oncology, a Member of the Royal College of Physicians, a Fellow of the Royal College of Radiologists (Clinical Oncology) and a Member of Faculty of Pharmaceutical Medicine.

For more information visit gtcbio.com/.

Agency / Source: GTCbio - Biopharmaceutical Conference

Availability: All Metropolitan Area

Traffic Booster: [/] Quick NewswireToday Visibility Checker

Distribution / Indexing: [+]